Related Experiment Video
Updated: Nov 3, 2025

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
Published on: April 3, 2016
Risk factors for rapid axial length elongation with low concentration atropine for myopia control
Aicun Fu1, Fiona Stapleton2, Li Wei1
1The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe road, Zhengzhou, 450000, China.
Insights
Younger children using lower concentration 0.01% atropine eye drops may experience rapid axial length elongation. This myopia progression is linked to shorter baseline axial length and smaller pupil diameter changes over 12 months.
Area of Science:
- Ophthalmology
- Pediatric Ophthalmology
- Myopia Control
Background:
- Myopia is a growing global health concern, particularly in children.
- Effective myopia control strategies are crucial to prevent high myopia and associated ocular pathologies.
- Low-dose atropine eye drops are a recognized treatment for slowing myopia progression.
Purpose of the Study:
- To identify risk factors associated with rapid axial length (AL) elongation in myopic children undergoing atropine treatment.
- To compare the effects of 0.01% and 0.02% atropine concentrations on myopia progression.
- To analyze the relationship between baseline characteristics and AL changes over a 12-month period.
Main Methods:
- A randomized study involving 328 myopic children using either 0.01% or 0.02% atropine.
- Collection of baseline and 1-year data including age, BMI, refractive error (SER), anterior chamber depth (ACD), and axial length (AL).
- Statistical analyses (univariate and multivariate logistic regression) to determine predictors of rapid AL elongation (>0.36 mm/year).
Main Results:
- Rapid AL elongation was associated with younger age at baseline (P < 0.0001).
- Use of 0.01% atropine was linked to increased risk of rapid AL elongation (P = 0.04).
- Shorter baseline AL (P = 0.03) and smaller changes in pupil diameter (P = 0.04) were also significant predictors.
Conclusions:
- Younger children with shorter baseline axial length are at higher risk for rapid AL elongation.
- The lower concentration of 0.01% atropine may be less effective in preventing rapid axial length growth compared to higher concentrations.
- Smaller changes in pupil diameter during treatment may indicate a higher risk of myopia progression.
Abstract:
Three hundred and twenty-eight myopic children, randomized to use either 0.01% (N = 166) or 0.02% (N = 162) atropine were enrolled in this study. Gender, age, body mass index(BMI), parental myopia status, atropine concentration used, pupil diameter, amplitude of accommodation, spherical equivalent refractive error (SER), anterior chamber depth (ACD) and axial length (AL) were collected at baseline and 1 year after using atropine. Rapid AL elongation was defined as > 0.36 mm growth per year. Univariate analyses showed that children with rapid AL elongation tend to be younger, have a smaller BMI, use of 0.01% atropine, narrow ACD, lower SER, shorter AL, smaller change in pupil diameter between 1 year and baseline (all P < 0.05). Multivariate logistic regression analyses confirmed that rapid AL elongation was associated with children that were younger at baseline (P < 0.0001), use of 0.01% atropine (P = 0.04), a shorter baseline AL (P = 0.03) and a smaller change in pupil diameter between 1 year and baseline (P = 0.04). Younger children with shorter AL at baseline, less change in their pupil diameter with atropine treatment and using the lower of the two atropine concentrations may undergo rapid AL elongation over a 12 months myopia control treatment period.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Focusing of Light in the Eye
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Accessory Structures of the Eye

